The Medicare GLP-1 Bridge currently includes: Foundayo tablets ( NDCs: 0002-4178-31, 0002-4503-31, 0002-4794-31, 0002-4803-31, 0002-4839-31, 0002-4953-31) Wegovy injections (NDCs: 0169-4525-14, 0169-4505-14, 0169-4501-14, 0169-4517-14, 0169-4524-14, 0169-4572-14) Wegovy tablets (NDCs: 0169-4415-31, 0169-4404-31, 0169-4409-31, 0169-4425-31) Zepbound KwikPen (NDCs: 0002-3566-11, 0002-3555-11, 0002-3544-11, 0002-3533-11, 0002-3522-11, and 0002-3511-11) The following products are not included: Ozempic Mounjaro Compounded semaglutide Compounded tirzepatide Zepbound single-dose vials Zepbound single-dose pens Some of these medications may still be covered through regular Medicare Part D when prescribed for certain medical conditions
What is particularly notable about the CagriSema combination is the much better side effect profile while still retaining body weight loss, comparable to other GLP1R/GIPR dual agonists
10.1159/000351088 Dev
Specifically, berberine can cause: Nausea Diarrhea Stomach cramps Bloating Headache Constipation (particularly when you stop taking it) Rashes (though this is relatively rare) The more berberine you take, the more likely you are to experience these side effects
Think of glutathione as the bodys internal cleaning crew
